Cargando…

Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study

BACKGROUND: Some current evidence is pointing towards an association between COVID-19 and worsening of multiple sclerosis (MS), stressing the importance of preventing COVID-19 among people with MS (pwMS). However, population-based evidence regarding the long-term post-COVID-19 course of relapsing-re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Etemadifar, Masoud, Abhari, Amir Parsa, Nouri, Hosein, Salari, Mehri, Maleki, Shiva, Amin, Alireza, Sedaghat, Nahad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861623/ https://www.ncbi.nlm.nih.gov/pubmed/35193507 http://dx.doi.org/10.1186/s12883-022-02590-9

Ejemplares similares

Association of COVID-19 with Disability Progression and Disease Exacerbation in People with Relapsing-Remitting Multiple Sclerosis: Evidence from a Year-Long Observational Study
por: Sedaghat, Nahad, et al.
Publicado: (2022)

Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2023)

Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
por: Etemadifar, Masoud, et al.
Publicado: (2022)

COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Successful seroconversion following mild COVID-19 contraction in a double-vaccinated B-cell-depleted person with multiple sclerosis: A hint towards booster efficacy?
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Multiple sclerosis in sarcoidosis patients: Two case reports
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Movement Disorders Associated with COVID-19
por: Salari, Mehri, et al.
Publicado: (2021)

Post-COVID-19 acute disseminated encephalomyelitis: Case report and review of the literature
por: Etemadifar, Masoud, et al.
Publicado: (2022)

SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Epidemiological and clinical features of pediatric-onset multiple sclerosis: A population-based study in Isfahan, Iran, between 1997-2020
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity
por: Sedaghat, Nahad, et al.
Publicado: (2023)

Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study
por: Tabrizi, Nasim, et al.
Publicado: (2012)

The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
por: Abdar, Morteza, et al.
Publicado: (2016)

Myasthenia gravis and coronavirus disease 2019: A report from Iran
por: Etemadifar, Masoud, et al.
Publicado: (2021)

Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
por: Etemadifar, Masoud, et al.
Publicado: (2011)

Interferon beta-1b-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in a patient treated for multiple sclerosis: A case report
por: Etemadifar, Masoud, et al.
Publicado: (2018)

Complete horizontal gaze palsy due to bilateral paramedian pontine reticular formation involvement as a presentation of multiple sclerosis: a case report
por: Akhavan Sigari, Amirhossein, et al.
Publicado: (2019)

Cooccurrence of Chorea-Acanthocytosis and Mesial Temporal Sclerosis: A Possible Role of Caudate Nucleus
por: Salari, Mehri, et al.
Publicado: (2017)

Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model
por: Najarzadegan, Niloofar, et al.
Publicado: (2022)

WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies
por: Etemadifar, M., et al.
Publicado: (2020)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study
por: Sedaghat, Nahad
Publicado: (2021)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Evaluation of S100A12 and Apo-A1 plasma level potency in untreated new relapsing–remitting multiple sclerosis patients and their family members
por: Samangooei, Mahsa, et al.
Publicado: (2022)

Prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis
por: Traboulsee, Anthony L, et al.
Publicado: (2016)

Can COVID‐19 accelerate neurodegeneration?
por: Salari, Mehri, et al.
Publicado: (2021)

Systemic Sclerosis, Reversible Cerebral Vasoconstriction Syndrome, and NeuroMyelitis Optica in a Patient
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Optic coherence tomography findings in relapsing-remitting multiple sclerosis patients of the northwest of Iran
por: Talebi, Mahnaz, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tti0haq23u3g9iqgjvfghb2h0f